Matches in Wikidata for { <http://www.wikidata.org/entity/Q90068766> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- Q90068766 description "article scientifique publié en 2017" @default.
- Q90068766 description "artículu científicu espublizáu en xunu de 2017" @default.
- Q90068766 description "scientific article published on 01 June 2017" @default.
- Q90068766 description "wetenschappelijk artikel" @default.
- Q90068766 description "наукова стаття, опублікована в червні 2017" @default.
- Q90068766 name "Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts)" @default.
- Q90068766 name "Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts)" @default.
- Q90068766 type Item @default.
- Q90068766 label "Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts)" @default.
- Q90068766 label "Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts)" @default.
- Q90068766 prefLabel "Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts)" @default.
- Q90068766 prefLabel "Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts)" @default.
- Q90068766 P1433 Q90068766-92C6DAB4-B486-4EB2-8638-FB124ECC311C @default.
- Q90068766 P1476 Q90068766-B3114BFE-725B-4515-BDCA-5C7F0A1B79EE @default.
- Q90068766 P2093 Q90068766-066FF67A-AE04-4DB1-83E3-5212B6659D37 @default.
- Q90068766 P2093 Q90068766-1A291684-F392-4305-A315-B7C213D36C3E @default.
- Q90068766 P2093 Q90068766-31D4492F-BECE-4879-A8E8-2C4DF0837589 @default.
- Q90068766 P2093 Q90068766-46A43F7A-A56A-4921-84B3-2977883EE928 @default.
- Q90068766 P2093 Q90068766-48685174-BE3F-46D2-8864-1DB95487EDAA @default.
- Q90068766 P2093 Q90068766-497A04D6-EB08-4121-8E85-414F7E9A3CB5 @default.
- Q90068766 P2093 Q90068766-6662CD3E-F6A4-46BC-8664-B1FFBE8B2DB9 @default.
- Q90068766 P2093 Q90068766-74595805-7598-4218-B56E-2310E82F561A @default.
- Q90068766 P2093 Q90068766-74D0F067-FF24-46EE-BB22-64B88CF8F8F4 @default.
- Q90068766 P2093 Q90068766-802A7172-C353-4416-B86C-4007A13C0D44 @default.
- Q90068766 P2093 Q90068766-817EDB25-BC1E-4383-A222-689CD1B92DF0 @default.
- Q90068766 P2093 Q90068766-8EBB94C5-254C-4ECD-B4F3-C4CF67E3C804 @default.
- Q90068766 P2093 Q90068766-93BFB30B-CB7F-440D-9D3C-FEA635A0027A @default.
- Q90068766 P2093 Q90068766-A564D48E-02AE-44C3-8E6B-FE701C3B08B4 @default.
- Q90068766 P2093 Q90068766-C918065C-0804-4C75-93C3-197D03929CE9 @default.
- Q90068766 P2093 Q90068766-D54C0480-0F0C-4F11-9000-7F07251670E1 @default.
- Q90068766 P304 Q90068766-1405AD12-C4EA-44B9-84ED-29B8F98989F5 @default.
- Q90068766 P31 Q90068766-A43676A2-8B42-48FD-935A-1D5D59BBDF18 @default.
- Q90068766 P356 Q90068766-8AEDCC25-97E8-432C-9903-B609AB1A369B @default.
- Q90068766 P478 Q90068766-FD880C27-9A5D-41DC-9AE3-3EA94D4345CE @default.
- Q90068766 P50 Q90068766-336A372E-F0CE-434F-9EF2-E84D1A66EEFB @default.
- Q90068766 P577 Q90068766-B46435F2-C102-485E-9B02-11851DDC3636 @default.
- Q90068766 P921 Q90068766-271D4CA4-243B-4737-81AE-D3017BFF308A @default.
- Q90068766 P921 Q90068766-AEE30DEA-56F1-48B3-8543-BA02340173FE @default.
- Q90068766 P921 Q90068766-FB636115-2E27-43CB-9CE0-4C19B561CD3E @default.
- Q90068766 P356 MDX302.002 @default.
- Q90068766 P1433 Q326122 @default.
- Q90068766 P1476 "Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts)" @default.
- Q90068766 P2093 "A Grothey" @default.
- Q90068766 P2093 "A Starodub" @default.
- Q90068766 P2093 "B Adesunloye" @default.
- Q90068766 P2093 "B H O'Neil" @default.
- Q90068766 P2093 "B Nadeau" @default.
- Q90068766 P2093 "C J Li" @default.
- Q90068766 P2093 "D Jonker" @default.
- Q90068766 P2093 "J Bendell" @default.
- Q90068766 P2093 "J Edenfield" @default.
- Q90068766 P2093 "J Hubbard" @default.
- Q90068766 P2093 "J Peyton" @default.
- Q90068766 P2093 "J Zubkus" @default.
- Q90068766 P2093 "L Borodyansky" @default.
- Q90068766 P2093 "T Halfdanarson" @default.
- Q90068766 P2093 "W Li" @default.
- Q90068766 P2093 "Y Z Li" @default.
- Q90068766 P304 "iii150-iii151" @default.
- Q90068766 P31 Q13442814 @default.
- Q90068766 P356 "10.1093/ANNONC/MDX302.002" @default.
- Q90068766 P478 "28 Suppl 3" @default.
- Q90068766 P50 Q107054204 @default.
- Q90068766 P577 "2017-06-01T00:00:00Z" @default.
- Q90068766 P921 Q108566365 @default.
- Q90068766 P921 Q188874 @default.
- Q90068766 P921 Q413299 @default.